The Chan Zuckerberg Initiative (CZI) is a philanthropy founded by Facebook co-founder Mark Zuckerberg and his wife Priscilla Chan in 2015. CZI's mission is to help build a more inclusive, just, and healthy society through partnerships with organizations working at the intersection of technology, community, and science [1]. Within its science portfolio, CZI has made significant investments in understanding the fundamental biology of neurodegenerative diseases through the Neurodegeneration Challenge Network.
¶ CZI Mission and Focus Areas
CZI's approach to philanthropy is distinctively technology-driven and results-oriented. The organization focuses on several core areas:
- Science: Advancing human health through fundamental biomedical research
- Education: Supporting students and teachers in reaching their full potential
- Community: Building stronger, more connected communities
- Justice & Opportunity: Addressing systemic inequities
Within science, CZI's focus spans from basic research to clinical applications, with particular emphasis on understanding cell biology, developing new therapeutic approaches, and creating open-access tools and datasets that accelerate scientific progress [2].
The Neurodegeneration Challenge represents CZI's flagship initiative targeting Alzheimer's disease, Parkinson's disease, and related disorders. Launched in 2018, the initiative takes a collaborative, cross-disciplinary approach to understanding the biological mechanisms underlying neurodegeneration.
- Understanding Disease Mechanisms: Fundamentally understand how neurodegenerative diseases develop and progress at the cellular and molecular level
- Accelerating Therapeutic Development: Identify new therapeutic targets and approaches
- Open Science: Promote open sharing of data, tools, and research findings
- Collaborative Research: Foster interdisciplinary collaboration between biologists, engineers, computational scientists, and clinicians
CZI has committed substantial resources to neurodegeneration research. The Neurodegeneration Challenge Network has funded multiple cohorts of research teams with grants typically ranging from $1-2 million per team over 2-3 year periods. The initiative has funded dozens of research teams across academic institutions worldwide [3].
CZI is a prominent advocate for open science practices. The organization's open science philosophy includes:
- Precompetitive Collaboration: CZI encourages grantees to share data and findings before publication in proprietary settings
- Public Data Repositories: Funded research must deposit data in publicly accessible repositories
- Data Standards: Emphasis on standardized data formats that facilitate reuse and integration
- Software Development: CZI supports development of open-source software for scientific analysis
- Cell Annotation Tools: Funding for tools like cellxgene that enable exploratory analysis of single-cell data
- Infrastructure: Support for platforms that democratize access to scientific tools
- Publication Requirements: Grantees are encouraged to publish in open-access journals
- Preprint Support: Promotion of preprint servers to accelerate dissemination of findings
- Article Processing Charges: CZI provides funding to cover open-access publication fees
The Neurodegeneration Challenge Network (NDCN) brings together researchers from diverse backgrounds to tackle neurodegeneration from multiple angles. The network includes:
- Basic Scientists: Researchers studying fundamental cellular and molecular biology
- Clinical Researchers: Clinicians working with patient populations
- Computational Biologists: Scientists applying machine learning and computational approaches
- Engineers: Researchers developing new technologies and tools
Funded projects span multiple aspects of neurodegeneration research:
- Amyloid and tau biology
- Neuroinflammation mechanisms
- Synaptic dysfunction
- Metabolic alterations in neurodegeneration
- Alpha-synuclein pathology
- Mitochondrial dysfunction
- Neuroimmune interactions
- Protein aggregation mechanisms
- Single-cell analysis of brain cells
- Multi-omics approaches
- Biomarker discovery
- Therapeutic target identification
¶ Key Grantees and Research Areas
While specific grantee lists change with each funding cycle, the NDCN has supported researchers from leading institutions worldwide. Research teams have included investigators from:
- Stanford University
- University of California system (UCSF, UC San Diego, UCLA)
- Massachusetts General Hospital/Harvard Medical School
- University of Cambridge
- Max Planck Institutes
- Karolinska Institutet
- Single-Cell Genomics: Teams using single-cell RNA sequencing to characterize brain cell types in neurodegenerative diseases
- iPSC Models: Researchers developing induced pluripotent stem cell models to study disease mechanisms
- Organoid Technology: Teams creating brain organoids to model neurodegeneration
- Computational Approaches: Groups applying machine learning to identify disease patterns and predict therapeutic outcomes
¶ Biohub and CZI Science Infrastructure
The CZ Biohub is a key component of CZI's science strategy. Founded in 2016 as a collaboration between CZI and leading California universities, the Biohub brings together researchers from Stanford, UCSF, and UC Berkeley to pursue ambitious scientific goals [4].
- AI for Biology: Developing machine learning models to understand cellular biology
- Cell Atlas: Creating comprehensive maps of cell types in human tissues
- Imaging Technologies: Advancing microscopy and imaging approaches
- Infectious Disease: Rapid response to emerging infectious diseases
The Biohub's cell atlas work directly benefits neurodegeneration research by providing foundational data on cell types in the brain. The AI and imaging capabilities developed at the Biohub are being applied to understanding neurodegenerative disease mechanisms.
¶ Collaborations and Partnerships
CZI works with academic institutions through:
- Multi-institutional Research Teams: Funding collaborative projects across universities
- Biohub Model: Direct partnership with Stanford, UCSF, and UC Berkeley
- Consortium Participation: Supporting international research consortia
While primarily funding academic research, CZI:
- Encourages industry engagement with funded projects
- Supports initiatives that bridge academic and commercial development
- Funds translational research that could lead to therapeutic development
CZI collaborates with patient advocacy organizations to:
- Ensure research addresses patient needs
- Facilitate access to patient samples and data
- Support patient engagement in research
¶ Impact and Outcomes
The Neurodegeneration Challenge has contributed to:
- Hundreds of peer-reviewed publications
- Development of new research tools and datasets
- Identification of novel disease mechanisms
- Training of next-generation researchers
The initiative has helped:
- Create a collaborative network of neurodegeneration researchers
- Foster interdisciplinary approaches to disease research
- Promote open science practices in the field
CZI's neurodegeneration research continues to evolve. Current priorities include:
- Deepening Understanding: More detailed mechanistic studies of disease processes
- Translation: Moving from basic discoveries toward therapeutic development
- Data Integration: Combining diverse data types to create comprehensive disease models
- Global Reach: Expanding the international scope of funded research
For more information on related organizations working in neurodegenerative disease research, see: